Physician
Endocrinology
Dr. Sherwyn L. Schwartz, MD
|
|
Give Review
Dr. Sherwyn L. Schwartz practices Endocrinology. He over the years received 2 awards: "Super Doctor" and "Top MD". Sherwyn L. Schwartz is a published doctor. He published 26 publications, including: 'A Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy.' Sherwyn Schwartz accepts Medicare payments and is registered with Medicare.gov.
Publications
- A Pooled Analysis Evaluating the Efficacy and Tolerability of Tapentadol Extended Release for Chronic, Painful Diabetic Peripheral Neuropathy.
- Saxagliptin for the treatment of type 2 Diabetes mellitus: Focus on recent studies.
- Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Pati...
- Effects of saxagliptin on β-cell stimulation and insulin secretion in patients with type 2 Diabetes.
- Treatment of elderly patients with type 2 Diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.
- Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 Diabetes mellitus.
- The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 Diabetes: a pilot study.
- Comparative device assessments: Humalog KwikPen compared With vial and syringe and FlexPen.
- United States patient preference and usability for the new disposable insulin device Solostar versus Other disposable pens.
- Population exposure-response modeling of metformin in patients with type 2 Diabetes mellitus.
- Safety profile and metabolic effects of 14 days of treatment With DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-g...
- Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 Diabetes: a randomized, double-blind, two-arm, parallel-group, place...
- Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison With frequent laboratory reference measurements.
- Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydroc...
- Dextromethorphan and quinidine in adult patients With uncontrolled painful diabetic peripheral neuropathy: a 29-day, multicenter, open-label, dose-escalation study.
- Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
- Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study.
- Insulin pharmacokinetics following dosing With Technosphere insulin in subjects With chronic obstructive pulmonary disease.
- Effects of sulodexide in patients with type 2 Diabetes and persistent albuminuria.
- Diabetes and dyslipidaemia.
- Metformin extended release for the treatment of type 2 Diabetes mellitus.
- Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 Diabetes.
- Static magnetic field therapy for symptomatic Diabetic neuropathy: a randomized, double-blind, placebo-controlled trial.
- Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 Diabetes: results of a 6-month, randomized, compara...
- Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use.
Schools
Univ Of Il Coll Of Med
Procedures Preformed
- Continuous Glucose Monitoring
Conditions Treated
- Abnormal Thyroid
- Adrenogenital Disorders
- Calcium Metabolism Disorders
- Diabetes Type 1
- View All
Doctors Specialties
- Endocrinology
Accepted Insurances
- Choice Plus POS II
- Superior Health Plan
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- First Health (Coventry Health Care) PPO
- Choice Care PPO
- Preferred PPO
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
Awards
- Super Doctor
- Top MD
Education
-
Rush University Medical Center
Hospital
-
CHRISTUS Santa Rosa Health System
Drug Facts
| NPI NUMBER | 1285692871 | |
| NPPES Provider LastName | SCHWARTZ | |
| NPPES Provider FirstName | SHERWYN | |
| NPPES Provider ZIPCode | 78229 | |
| NPPES Provider State | TX | |
| Specialty Description | Endocrinology | |
| Total Claim Count | 9666.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 89.0 | |
| Percent Opioid Claims | 0.92 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285692871 |
| Last Name Of The Provider | SCHWARTZ |
| First Name Of The Provider | SHERWYN |
| View All |
Similar Doctors
|
|
Dr. Kathleen E. Hands, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaime O. Cruz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Forest P. Newman III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ralph A. Defronzo, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Blake E. Elkins, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vijayveer S. Pamar, MD
This Doctor is OpenDoctor Recommended.
|